Axitinib + Ipilimumab in Advanced Melanoma

NCT04996823 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Ipilimumab
DRUG: Axitinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]